Skip to main content

Ayman Koteish, MD

Ayman Koteish, MD

Medical Director of Liver Transplant Director of Hepatology

Transplant

Ayman Koteish

Overview

Ayman Koteish, MD, joined the AdventHealth Transplant Institute in the summer of 2014 as the Director of Hepatology and the Medical Director of Liver Transplant Services. He most recently served as an assistant professor of medicine at the Johns Hopkins University School of Medicine in Baltimore where he was the Director of the Liver Transplant Fellowship Program and the Medical Director of Live Donor Liver Transplantation. He has extensive research and publication experience in liver disease.

Articles

Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage

HEPATOLOGY

2020

Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Re-Evaluating Age Limits in Transplantation Consortium

LIVER TRANSPLANTATION

2020

Workforce in Hepatology: Update and a Critical Need for More Information

HEPATOLOGY

2017

Hepatopulmonary Syndrome Is a Frequent Cause of Dyspnea in the Short Telomere Disorders

CHEST

2015

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

2015

Entrustable professional activities for gastroenterology fellowship training

GASTROINTESTINAL ENDOSCOPY

2014

Clinical Decision-Making by Gastroenterologists and Hepatologists for Patients with Early Hepatocellular Carcinoma

ANNALS OF SURGICAL ONCOLOGY

2014

Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III

JOURNAL OF GASTROENTEROLOGY

2013

Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study

HEPATOLOGY INTERNATIONAL

2013

Meta-analysis: vitamin D and non-alcoholic fatty liver disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

2013

Education & Training

Education

American University of Beirut

Residency

Good Samaritan Hospital - Johns Hopkins University affiliate;
Good Samaritan Hospital

Fellowship

Johns Hopkins Hospital;
John Hopkins School of Medicine

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT04849728

'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis”
'

Icon for trial | 337HNAS20011 'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibros

This study is currently enrolling.

Inventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and ...